Physicochemical interaction of rifampicin and ritonavir-lopinavir solid dispersion: an in-vitro and ex-vivo investigation

References

• Global Tuberculosis reporT 2022. 2022.
   Google Scholar
• Grobbelaar M, Louw GE, Sampson SL, et al. Evolution of rifampicin treatment for tuberculosis. Infect Genet Evol. 2019;74:103937. doi: 10.1016/j.meegid.2019.103937.
   PubMed Web of Science ®Google Scholar
• Bobat R. HIV infection in children and adolescents. Cham: Springer International Publishing; 2020.
   Google Scholar
• Masquelier B, Breilh D, Neau D, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2002;46(9):2926–2932. doi: 10.1128/AAC.46.9.2926-2932.2002.
   PubMed Web of Science ®Google Scholar
• Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002;16(1):75–83. doi: 10.1097/00002030-200201040-00010.
   PubMed Web of Science ®Google Scholar
• Singh S, Mariappan TT, Sankar R, et al. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. 2001;228(1–2):5–17. doi: 10.1016/s0378-5173(01)00754-2.
   Google Scholar
• Abulfathi AA, Decloedt EH, Svensson EM, et al. Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis. Clin Pharmacokinet. 2019;58(9):1103–1129. doi: 10.1007/s40262-019-00764-2.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Meintjes G, Burman WJ, et al. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007;196 (Suppl 1):S63–75. doi: 10.1086/518655.
   PubMed Web of Science ®Google Scholar
• Becker C, Dressman JB, Junginger HE, et al. Biowaiver monographs for immediate release solid oral dosage forms: rifampicin. J Pharm Sci. 2009;98(7):2252–2267. doi: 10.1002/jps.21624.
   PubMed Web of Science ®Google Scholar
• de Pinho Pessoa Nogueira L, de Oliveira YS, de C. Fonseca J, et al. Crystalline structure of the marketed form of rifampicin: a case of conformational and charge transfer polymorphism. J Mol Struct. 2018;1155:260–266. doi: 10.1016/j.molstruc.2017.10.083.
   Web of Science ®Google Scholar
• Gadret M, Goursolle M, Leger JM, et al. Structure cristalline de la rifampicine C43N4O12H58.5H2O. Acta Crystallogr B Struct Crystallogr Cryst Chem. 1975;31(5):1454–1462. doi: 10.1107/S0567740875005407.
   Google Scholar
• Przybylski P, Pyta K, Klich K, et al. 13C and 15N CP/MAS, 1H-15N SCT CP/MAS and FTIR spectroscopy as tools for qualitative detection of the presence of zwitterionic and nonionic forms of ansa-macrolide 3-formylrifamycin SV and its derivatives in solid state+. Magn Reson Chem. 2014;52(1-2):10–21. doi: 10.1002/mrc.4028.
   PubMed Web of Science ®Google Scholar
• Pyta K, Przybylski P, Wicher B, et al. Intramolecular proton transfer impact on antibacterial properties of ansamycin antibiotic rifampicin and its new amino analogues. Org Biomol Chem. 2012;10(12):2385–2388. doi: 10.1039/c2ob00008c.
   PubMed Web of Science ®Google Scholar
• Wicher B, Pyta K, Przybylski P, et al. Redetermination of rifampicin penta-hydrate revealing a zwitterionic form of the anti-biotic. Acta Crystallogr C. 2012;68(5):209–212.
   Google Scholar
• Henwood SQ, Liebenberg W, Tiedt LR, et al. Characterization of the solubility and dissolution properties of several new rifampicin polymorphs. Solvates Hydrates. 2001;27(10):1017–1030. doi: 10.1081/ddc-100108364.
   Google Scholar
• Angiolini L, Agnes M, Cohen B, et al. Formation, characterization and pH dependence of rifampicin: heptakis(2,6-di-O-methyl)-β-cyclodextrin complexes. Int J Pharm. 2017;531(2):668–675. doi: 10.1016/j.ijpharm.2017.06.015.
   PubMedGoogle Scholar
• Londhe O, Sanjay Mane S, Umesh Hirlekar B, et al. In vitro, in-vivo, and in-silico investigation of physicochemical interactions between pioglitazone and rifampicin. Eur J Pharm Biopharm. 2023;188:54–65. doi: 10.1016/j.ejpb.2023.05.006.
   PubMed Web of Science ®Google Scholar
• Hurst S, Loi C-M, Brodfuehrer J, et al. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin Drug Metab Toxicol. 2007;3(4):469–489. doi: 10.1517/17425255.3.4.469.
   PubMed Web of Science ®Google Scholar
• Trasi NS, Taylor LS. Thermodynamics of highly supersaturated aqueous solutions of poorly Water-Soluble Drugs - Impact of a second drug on the solution phase behavior and implications for combination products. J Pharm Sci. 2015;104(8):2583–2593. doi: 10.1002/jps.24528.
   PubMed Web of Science ®Google Scholar
• Taylor LS, Zhang GGZ. Physical chemistry of supersaturated solutions and implications for oral absorption. Adv Drug Deliv Rev. 2016;101:122–142. doi: 10.1016/j.addr.2016.03.006.
   PubMed Web of Science ®Google Scholar
• Trasi NS, Taylor LS. Dissolution performance of binary amorphous drug combinations - Impact of a second drug on the maximum achievable supersaturation. Int J Pharm. 2015;496(2):282–290. doi: 10.1016/j.ijpharm.2015.10.026.
   PubMedGoogle Scholar
• Sai Krishna Anand V, Sakhare SD, Navya Sree KS, et al. The relevance of co-amorphous formulations to develop supersaturated dosage forms: in-vitro, and ex-vivo investigation of Ritonavir-Lopinavir co-amorphous materials. Eur J Pharm Sci. 2018;123:124–134. doi: 10.1016/j.ejps.2018.07.046.
   PubMed Web of Science ®Google Scholar
• Alhalaweh A, Bergström CAS, Taylor LS. Compromised in vitro dissolution and membrane transport of multidrug amorphous formulations. J Control Release. 2016;229:172–182. doi: 10.1016/j.jconrel.2016.03.028.
   PubMed Web of Science ®Google Scholar
• Shete S, Reddy SC, Lakshman YD, et al. Implications of phase solubility/miscibility and drug-rich phase formation on the performance of co-amorphous materials: the case of darunavir co-amorphous materials with ritonavir and indomethacin as co-formers. Int J Pharm. 2021;608:121119. doi: 10.1016/j.ijpharm.2021.121119.
   PubMedGoogle Scholar
• Sugawara M, Kadomura S, He X, et al. The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations. Eur J Pharm Sci. 2005;26(1):1–8. doi: 10.1016/j.ejps.2005.02.017.
   PubMed Web of Science ®Google Scholar
• Kostewicz ES, Brauns U, Becker R, et al. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm Res. 2002;19(3):345–349. doi: 10.1023/a:1014407421366.
   PubMed Web of Science ®Google Scholar
• Vertzoni M, Dressman J, Butler J, et al. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur J Pharm Biopharm. 2005;60(3):413–417. doi: 10.1016/j.ejpb.2005.03.002.
   PubMed Web of Science ®Google Scholar
• Hsieh YL, Ilevbare GA, Van Eerdenbrugh B, et al. PH-Induced precipitation behavior of weakly basic compounds: determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties. Pharm Res. 2012;29(10):2738–2753. doi: 10.1007/s11095-012-0759-8.
   PubMed Web of Science ®Google Scholar
• Culen M, Rezacova A, Jampilek J, et al. Designing a dynamic dissolution method: a review of instrumental options and corresponding physiology of stomach and small intestine. J Pharm Sci. 2013;102(9):2995–3017. doi: 10.1002/jps.23494.
   PubMed Web of Science ®Google Scholar
• Psachoulias D, Vertzoni M, Goumas K, et al. Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults. Pharm Res. 2011;28(12):3145–3158. doi: 10.1007/s11095-011-0506-6.
   PubMed Web of Science ®Google Scholar
• Indulkar AS, Gao Y, Raina SA, et al. Exploiting the phenomenon of liquid–liquid phase separation for enhanced and sustained membrane transport of a poorly water-soluble drug. Mol Pharm. 2016;13(6):2059–2069. doi: 10.1021/acs.molpharmaceut.6b00202.
   PubMedGoogle Scholar
• Sakhare SD, Anand VSK, Karan A, et al. The assessment of pH-induced supersaturation and impact of an additional drug on the solution phase behavior of saquinavir. J Pharm Innov. 2019;14(4):305–315. doi: 10.1007/s12247-018-9357-6.
   Web of Science ®Google Scholar
• Sugihara H, Taylor LS. Evaluation of pazopanib phase behavior following pH-induced supersaturation. Mol Pharm. 2018;15(4):1690–1699. doi: 10.1021/acs.molpharmaceut.8b00081.
   PubMedGoogle Scholar
• Mosquera-Giraldo LI, Taylor LS. Glass-liquid phase separation in highly supersaturated aqueous solutions of telaprevir. Mol Pharm. 2015;12(2):496–503. doi: 10.1021/mp500573z.
   PubMedGoogle Scholar
• Siriwannakij N, Heimbach T, Serajuddin ATM. Aqueous dissolution and dispersion behavior of polyvinylpyrrolidone vinyl acetate-based amorphous solid dispersion of ritonavir prepared by hot-melt extrusion with and without added surfactants. J Pharm Sci. 2021;110(4):1480–1494. doi: 10.1016/j.xphs.2020.08.007.
   PubMed Web of Science ®Google Scholar
• Wu H, Wang Z, Zhao Y, et al. Effect of different seed crystals on the supersaturation state of ritonavir tablets prepared by hot-melt extrusion. Eur J Pharm Sci. 2023;185:106440. doi: 10.1016/j.ejps.2023.106440.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xie X, Zhao Y, et al. Effect of plasticizers on manufacturing ritonavir/copovidone solid dispersions via hot-melt extrusion: preformulation, physicochemical characterization, and pharmacokinetics in rats. Eur J Pharm Sci. 2019;127:60–70. doi: 10.1016/j.ejps.2018.10.020.
   PubMed Web of Science ®Google Scholar
• Moreira Pinheiro LB, Tao S, Culbertson E, et al. Evaluation of the polymorphic forms of ritonavir and lopinavir in raw materials and co-milled systems. Int J Pharm. 2022;628:122329. doi: 10.1016/j.ijpharm.2022.122329.
   PubMedGoogle Scholar
• Trasi NS, Bhujbal S, Zhou QT, et al. Amorphous solid dispersion formation via solvent granulation – a case study with ritonavir and lopinavir. Int J Pharm X. 2019;1:100035. doi: 10.1016/j.ijpx.2019.100035.
   PubMedGoogle Scholar
• Chegireddy M, Hanegave GK, Lakshman D, et al. The significance of utilizing in vitro transfer model and media selection to study the dissolution performance of weak ionizable bases: investigation using saquinavir as a model drug. AAPS PharmSciTech. 2020;21(2):47. doi: 10.1208/s12249-019-1563-0.
   PubMed Web of Science ®Google Scholar
• Yarlagadda DL, Anand VSK, Nair AR, et al. A computational-based approach to fabricate ceritinib co-amorphous system using a novel co-former rutin for bioavailability enhancement. Eur J Pharm Biopharm. 2023;190:220–230. doi: 10.1016/j.ejpb.2023.07.019.
   PubMed Web of Science ®Google Scholar
• Lakshman D, Chegireddy M, Hanegave GK, et al. Investigation of drug-polymer miscibility, biorelevant dissolution, and bioavailability improvement of dolutegravir-polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer solid dispersions. Eur J Pharm Sci. 2020;142:105137. doi: 10.1016/j.ejps.2019.105137.
   PubMed Web of Science ®Google Scholar
• Greenhalgh DJ, Williams AC, Timmins P, et al. Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci. 1999;88(11):1182–1190. doi: 10.1021/js9900856.
   PubMed Web of Science ®Google Scholar
• Forster A, Hempenstall J, Tucker I, et al. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int J Pharm. 2001;226(1–2):147–161. doi: 10.1016/s0378-5173(01)00801-8.
   Google Scholar
• Purohit HS, Taylor LS. Phase separation kinetics in amorphous solid dispersions upon exposure to water. Mol Pharm. 2015;12(5):1623–1635. doi: 10.1021/acs.molpharmaceut.5b00041.
   PubMed Web of Science ®Google Scholar
• Chiou WL, Keyphrases SR. Pharmaceutical applications of solid dispersion systems solid dispersion systems-review 0 dispersions, solid systems-review 0 absorption kinetics-solid dispersion systems, review dosage forms, fast-release solid dispersion systems. Rev Cont. 1971;60(9):1281–302. doi: 10.1002/jps.2600600902.
   Google Scholar
• Zi P, Zhang C, Ju C, et al. Solubility and bioavailability enhancement study of lopinavir solid dispersion matrixed with a polymeric surfactant - Soluplus. Eur J Pharm Sci. 2019;134:233–245. doi: 10.1016/j.ejps.2019.04.022.
   PubMed Web of Science ®Google Scholar
• Bhanderi A, Bari F, Al-Obaidi H. Evaluation of the impact of surfactants on miscibility of griseofulvin in spray dried amorphous solid dispersions. J Drug Deliv Sci Technol. 2021;64:102606. doi: 10.1016/j.jddst.2021.102606.
   Web of Science ®Google Scholar
• Henwood SQ, De Villiers MM, Liebenberg W, et al. Solubility and dissolution properties of generic rifampicin raw materials. Drug Dev Ind Pharm. 2000;26(4):403–408. doi: 10.1081/ddc-100101246.
   PubMed Web of Science ®Google Scholar
• Bevernage J, Brouwers J, Annaert P, et al. Drug precipitation-permeation interplay: supersaturation in an absorptive environment. Eur J Pharm Biopharm. 2012;82(2):424–428. doi: 10.1016/j.ejpb.2012.07.009.
   PubMed Web of Science ®Google Scholar
• Baird JA, Van Eerdenbrugh B, Taylor LS. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci. 2010;99(9):3787–3806. doi: 10.1002/jps.22197.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development q settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26. doi: 10.1016/s0169-409x(00)00129-0.
   Google Scholar
• Mariappan TT, Singh S. Evidence of efflux-mediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted gut sac techniques. Mol Pharm. 2004;1(5):363–367. doi: 10.1021/mp049937n.
   PubMedGoogle Scholar